Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial
Daniel H. Solomon, Olga Demler, Pamela M. Rist, L Santacroce, Ahmed Tawakol, Jon T. Giles, Katherine P. Liao, Joan M. Bathon
Abstract
Cardiovascular disease remains an important comorbidity in patients with rheumatoid arthritis (RA), but traditional models do not accurately predict cardiovascular risk in patients with RA. The addition of biomarkers could improve prediction. METHODS AND RESULTS: =0.0005). CONCLUSIONS: A candidate biomarker approach identified several promising biomarkers that associate with baseline and treatment-associated changes in arterial inflammation in patients with RA. These will now be tested in an external validation cohort.
Topics & Concepts
MedicineRheumatoid arthritisInternal medicineClinical trialRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchViral Infections and Immunology Research